Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes

Autoimmunity Reviews

Volumn 14, Issue 3, 2015, Pages 231-245

  Bonneau, J ^a   Dumestre Perard, C ^b   Rinaudo Gaujous, M ^a   Genin, C ^a   Sparrow, M ^c   Roblin, X ^d   Paul, S ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIV GRENOBLE ALPES   (France)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Crohn's disease; Glycan; GM CSF; GP2; IBD; Ulcerative colitis

Indexed keywords

GLYCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; ANTIBODY; BIOLOGICAL MARKER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GP2 PROTEIN, HUMAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POLYSACCHARIDE;

CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; HUMAN; ILEITIS; IRRITABLE COLON; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; SEROLOGY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; TREATMENT OUTCOME;

ANTIBODIES; BIOLOGICAL MARKERS; GPI-LINKED PROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATORY BOWEL DISEASES; POLYSACCHARIDES; TREATMENT OUTCOME;

EID: 84920971302     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.11.004     Document Type: Review

References (99)

1. Agius L.M. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. J Theor Biol 2004, 227:219-228. 10.1016/j.jtbi.2003.11.002.
2. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640. 10.1016/S0140-6736(07)60750-8.
3. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594. 10.1053/j.gastro.2007.11.059.
4. Cassinotti A., Sarzi-Puttini P., Fichera M., Shoenfeld Y., de Franchis R., Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev 2014, 13:1-2. 10.1016/j.autrev.2013.06.007.
5. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev 2014, 13:467-471. 10.1016/j.autrev.2014.01.029.
6. Conrad K., Roggenbuck D., Laass M.W. Diagnosis and classification of ulcerative colitis. Autoimmun Rev 2014, 13:463-466. 10.1016/j.autrev.2014.01.028.
7. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014, 13:24-30. 10.1016/j.autrev.2013.06.002.
8. Reese G.E., Constantinides V.A., Simillis C., Darzi A.W., Orchard T.R., Fazio V.W., et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006, 101:2410-2422. 10.1111/j.1572-0241.2006.00840.x.
9. Desir B., Amre D.K., Lu S., Ohman-strickland P., Dubinsky M., Fisher R., et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:139-146. 10.1016/S1542-3565(03)00321-5.
10. Esters N., Vermeire S., Joossens S., Noman M., Louis E., Belaiche J., et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002, 97:1458-1462. 10.1111/j.1572-0241.2002.05689.x.
11. Sandborn W.J., Landers C.J., Tremaine W.J., Targan S.R. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996, 71:431-436. 10.4065/71.5.431.
12. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181. 10.1373/clinchem.2005.058560.
13. Cohavy O., Bruckner D., Gordon L.K., Misra R., Wei B., Eggena M.E., et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000, 68:1542-1548.
14. Sutton C.L., Kim J., Yamane A., Dalwadi H., Wei B., Landers C., et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000, 119:23-31.
15. Wei B., Huang T., Dalwadi H., Sutton C.L., Bruckner D., Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun 2002, 70:6567-6575. 10.1128/IAI. 70.12.6567-6575.2002.
16. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296-1306. 10.1172/JCI200420295.
17. Mow W.S., Vasiliauskas E.A., Lin Y.-C., Fleshner P.R., Papadakis K.A., Taylor K.D., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
18. Spivak J., Landers C.J., Vasiliauskas E.A., Abreu M.T., Dubinsky M.C., Papadakis K.A., et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 2006, 12:1122-1130. 10.1097/01.mib.0000235833.47423.d7.
19. Dubinsky M.C., Lin Y.-C., Dutridge D., Picornell Y., Landers C.J., Farrior S., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006, 101:360-367. 10.1111/j.1572-0241.2006.00456.x.
20. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.-C., Braun J., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699.
21. Michielan A., Basso D., Martinato M., Pathak S., Banerjee A., Oliva L., et al. Increased antibody response to microbial antigens in patients with Crohn's disease and their unaffected first-degree relatives. Dig Liver Dis 2013, 10.1016/j.dld.2013.01.017.
22. Zholudev A., Zurakowski D., Young W., Leichtner A., Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99:2235-2241. 10.1111/j.1572-0241.2004.40369.x.
23. Dubinsky M.C., Kugathasan S., Mei L., Picornell Y., Nebel J., Wrobel I., et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008, 6:1105-1111. 10.1016/j.cgh.2008.04.032.
24. Arnott I.D.R., Landers C.J., Nimmo E.J., Drummond H.E., Smith B.K.R., Targan S.R., et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004, 99:2376-2384. 10.1111/j.1572-0241.2004.40417.x.
25. Devlin S.M., Yang H., Ippoliti A., Taylor K.D., Landers C.J., Su X., et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007, 132:576-586. 10.1053/j.gastro.2006.11.013.
26. Elkadri A.A., Stempak J.M., Walters T.D., Lal S., Griffiths A.M., Steinhart A.H., et al. Serum antibodies associated with complex inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:1499-1505. 10.1097/MIB.0b013e318281f2a1.
27. Markowitz J., Kugathasan S., Dubinsky M., Mei L., Crandall W., LeLeiko N., et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?. Inflamm Bowel Dis 2009, 15:714-719. 10.1002/ibd.20831.
28. Mei L., Targan S.R., Landers C.J., Dutridge D., Ippoliti A., Vasiliauskas E.A., et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006, 130:1078-1085. 10.1053/j.gastro.2006.02.013.
29. O'Donnell S., O'Sullivan M., O'Morain C.A., Ryan B.M. The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population. Eur J Gastroenterol Hepatol 2013, 25:1464-1469. 10.1097/MEG.0b013e328365a364.
30. Papadakis K.A., Yang H., Ippoliti A., Mei L., Elson C.O., Hershberg R.M., et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007, 13:524-530. 10.1002/ibd.20106.
31. Davis M.K., Andres J.M., Jolley C.D., Novak D.A., Haafiz A.B., González-Peralta R.P. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr 2007, 45:409-413. 10.1097/MPG.0b013e31812f7f6e.
32. Coukos J.A., Howard L.A., Weinberg J.M., Becker J.M., Stucchi A.F., Farraye F.A. ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis. Dig Dis Sci 2012, 57:1544-1553. 10.1007/s10620-012-2050-6.
33. Tyler A.D., Milgrom R., Xu W., Stempak J.M., Steinhart A.H., McLeod R.S., et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2012, 10:507-12.e1. 10.1016/j.cgh.2011.09.016.
34. Petersen A.M., Schou C., Mirsepasi H., Engberg J., Friis-Møller A., Nordgaard-Lassen I., et al. Seroreactivity to E. coli outer membrane protein C antibodies in active inflammatory bowel disease; diagnostic value and correlation with phylogroup B2 E. coli infection. Scand J Gastroenterol 2012, 47:155-161. 10.3109/00365521.2011.639080.
35. Iltanen S., Tervo L., Halttunen T., Wei B., Braun J., Rantala I., et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis 2006, 12:389-394. 10.1097/01.MIB.0000218765.84087.42.
36. Lichtenstein G.R., Targan S.R., Dubinsky M.C., Rotter J.I., Barken D.M., Princen F., et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011, 17:2488-2496. 10.1002/ibd.21661.
37. Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005, 128:2020-2028.
38. Fleshner P., Ippoliti A., Dubinsky M., Vasiliauskas E., Mei L., Papadakis K.A., et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008, 6:561-568. 10.1016/j.cgh.2008.01.002.
39. Truta B., Li D.X., Mahadevan U., Fisher E.R., Chen Y.-Y., Grace K., et al. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci 2014, 59:135-145. 10.1007/s10620-013-2866-8.
40. Ryan J.D., Silverberg M.S., Xu W., Graff L.A., Targownik L.E., Walker J.R., et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013, 38:274-283. 10.1111/apt.12368.
41. Schoepfer A.M., Schaffer T., Mueller S., Flogerzi B., Vassella E., Seibold-Schmid B., et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis 2009, 15:1358-1367. 10.1002/ibd.20892.
42. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006, 131:366-378. 10.1053/j.gastro.2006.04.030.
43. Papp M., Altorjay I., Dotan N., Palatka K., Foldi I., Tumpek J., et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008, 103:665-681. 10.1111/j.1572-0241.2007.01652.x.
44. Roggenbuck D., Hausdorf G., Martinez-Gamboa L., Reinhold D., Buttner T., Jungblut P.R., et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009, 58:1620-1628. 10.1136/gut.2008.162495.
45. Komorowski L., Teegen B., Probst C., Aulinger-Stöcker K., Sina C., Fellermann K., et al. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis 2013, 7:780-790. 10.1016/j.crohns.2012.10.011.
46. Bogdanos D.P., Rigopoulou E.I., Smyk D.S., Roggenbuck D., Reinhold D., Forbes A., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148. 10.1016/j.autrev.2011.09.004.
47. Werner L., Paclik D., Fritz C., Reinhold D., Roggenbuck D., Sturm A. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol 2012, 189:2774-2783. 10.4049/jimmunol.1103190.
48. Roggenbuck D., Reinhold D., Werner L., Schierack P., Bogdanos D.P., Conrad K. Glycoprotein 2 antibodies in Crohn's disease. Adv. Clin. Chem. 2013, vol. 60:187-208. Elsevier.
49. Yu S., Lowe A.W. The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli type 1 Fimbriae. BMC Gastroenterol 2009, 9:58. 10.1186/1471-230X-9-58.
50. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., et al. Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response. Nature 2009, 462:226-230. 10.1038/nature08529.
51. Roggenbuck D., Reinhold D., Wex T., Goihl A., von Arnim U., Malfertheiner P., et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta 2011, 412:718-724. 10.1016/j.cca.2010.12.029.
52. Egea L., Hirata Y., Kagnoff M.F. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol 2010, 4:723-731. 10.1586/egh.10.73.
53. Bernasconi E., Favre L., Maillard M.H., Bachmann D., Pythoud C., Bouzourene H., et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis 2010, 16:428-441. 10.1002/ibd.21072.
54. Egea L., McAllister C.S., Lakhdari O., Minev I., Shenouda S., Kagnoff M.F. GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa. J Immunol Baltim Md 1950 2013, 190:1702-1713. 10.4049/jimmunol.1202368.
55. Däbritz J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2014, 306:G455-G465. 10.1152/ajpgi.00409.2013.
56. Korzenik J.R., Dieckgraefe B.K., Valentine J.F., Hausman D.F., Gilbert M.J., Sargramostim in Crohn's Disease Study Group Sargramostim for active Crohn's disease. N Engl J Med 2005, 352:2193-2201. 10.1056/NEJMoa041109.
57. Jurickova I., Collins M.H., Chalk C., Seese A., Bezold R., Lake K., et al. Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity. Clin Exp Immunol 2013, 172:455-465. 10.1111/cei.12076.
58. Han X., Uchida K., Jurickova I., Koch D., Willson T., Samson C., et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009, 136:1261-71.e3. 10.1053/j.gastro.2008.12.046.
59. Homsak E., Micetić-Turk D., Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr 2010, 122(Suppl. 2):19-25. 10.1007/s00508-010-1344-y.
60. Lawrance I.C., Hall A., Leong R., Pearce C., Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005, 11:890-897.
61. Romas E., Paspaliaris B., d' Apice A.J., Elliott P.R. Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease. Aust N Z J Med 1992, 22:652-659.
62. Naser S.A., Hulten K., Shafran I., Graham D.Y., El-Zaatari F.A. Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol 2000, 77:497-504.
63. Wei B., Dalwadi H., Gordon L.K., Landers C., Bruckner D., Targan S.R., et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun 2001, 69:6044-6054. 10.1128/IAI. 69.10.6044-6054.2001.
64. Sakiyama T., Fujita H., Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflamm Bowel Dis 2008, 14:310-317. 10.1002/ibd.20328.
65. Faubion W.A., Fletcher J.G., O'Byrne S., Feagan B.G., de Villiers W.J., Salzberg B., et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 2013, 108:1891-1900. 10.1038/ajg.2013.354.
66. Prideaux L., Kamm M.A., De Cruz P., van Langenberg D.R., Ng S.C., Dotan I. Inflammatory bowel disease serology in Asia and the West. World J Gastroenterol 2013, 19:6207-6213. 10.3748/wjg.v19.i37.6207.
67. Rieder F., Hahn P., Finsterhoelzl L., Schleder S., Wolf A., Dirmeier A., et al. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort. Inflamm Bowel Dis 2012, 18:1221-1231. 10.1002/ibd.21854.
68. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010, 16:263-274. 10.1002/ibd.21046.
69. Koutroubakis I.E., Drygiannakis D., Tsirogianni A., Oustamanolakis P., Karmiris K., Papamichael K., et al. Antiglycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci 2010, 56:845-852. 10.1007/s10620-010-1328-9.
70. Simondi D., Mengozzi G., Betteto S., Bonardi R., Ghignone R.P., Fagoonee S., et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:645-651. 10.1002/ibd.20368.
71. Seow C.H., Stempak J.M., Xu W., Lan H., Griffiths A.M., Greenberg G.R., et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009, 104:1426-1434. 10.1038/ajg.2009.79.
72. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375. 10.1002/ibd.21179.
73. Malickova K., Lakatos P.L., Bortlik M., Komarek V., Janatkova I., Lukas M. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. Eur J Gastroenterol Hepatol 2010, 22:144-150.
74. Henckaerts L., Pierik M., Joossens M., Ferrante M., Rutgeerts P., Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007, 56:1536-1542. 10.1136/gut.2007.125468.
75. Rejchrt S., Drahosová M., Kopácová M., Cyrany J., Douda T., Pintér M., et al. Antilaminaribioside and antichitobioside antibodies in inflammatory bowel disease. Folia Microbiol (Praha) 2008, 53:373-376. 10.1007/s12223-008-0058-2.
76. Ferrante M., Henckaerts L., Joossens M., Pierik M., Joossens S., Dotan N., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403. 10.1136/gut.2006.108043.
77. Kaul A., Hutfless S., Liu L., Bayless T.M., Marohn M.R., Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis 2012, 18:1872-1884. 10.1002/ibd.22862.
78. Vandewalle-El Khoury P., Colombel J.-F., Joossens S., Standaert-Vitse A., Collot M., Halfvarson J., et al. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction. Am J Gastroenterol 2008, 103:949-957. 10.1111/j.1572-0241.2007.01648.x.
79. Beéck K.O.D., Vermeire S., Rutgeerts P., Bossuyt X. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2012, 61:162-164. 10.1136/gut.2010.233148.
80. Pavlidis P., Romanidou O., Roggenbuck D., Mytilinaiou M.G., Al-Sulttan F., Liaskos C., et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol 2012, 2012:1-8. 10.1155/2012/640835.
81. Bogdanos D., Roggenbuck D., Reinhold D., Wex T., Pavlidis P., von Arnim U., et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol 2012, 12:102.
82. Pavlidis P., Forbes A., Bogdanos D.P. Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK. Clin Chim Acta 2011, 412:1163-1164. 10.1016/j.cca.2011.02.005.
83. Gross S., Bakker S.F., van Bodegraven A.A., van Hoogstraten I.M.W., Gelderman K.A., Bouma G., et al. Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease. J Gastrointestin Liver Dis 2014, 23:127-133.
84. Bonaci-Nikolic B., Spuran M., Andrejevic S., Nikolic M. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap. Clin Chim Acta 2012, 413:822-823. 10.1016/j.cca.2012.01.005.
85. Roggenbuck D., Bogdanos D., Conrad K. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?. J Crohns Colitis 2013, 7:e273-e274. 10.1016/j.crohns.2012.12.013.
86. Gathungu G., Kim M.-O., Ferguson J.P., Sharma Y., Zhang W., Ng S.M.E., et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease. Inflamm Bowel Dis 2013, 19:1671-1680. 10.1097/MIB.0b013e318281f506.
87. Dykes D.M.H., Towbin A.J., Bonkowski E., Chalk C., Bezold R., Lake K., et al. Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies. Inflamm Bowel Dis 2013, 19:2146-2154. 10.1097/MIB.0b013e31829706e0.
88. Däbritz J., Bonkowski E., Chalk C., Trapnell B.C., Langhorst J., Denson L.A., et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol 2013, 108:1901-1910. 10.1038/ajg.2013.360.
89. Nylund C.M., D'Mello S., Kim M.-O., Bonkowski E., Däbritz J., Foell D., et al. Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J Pediatr Gastroenterol Nutr 2011, 52:542-548. 10.1097/MPG.0b013e3181fe2d93.
90. Ferrante M., Declerck S., Coopmans T., De Hertogh G., Van Assche G., Penninckx F., et al. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes. J Crohns Colitis 2008, 2:142-151. 10.1016/j.crohns.2007.10.003.
91. Werner L., Sturm A., Roggenbuck D., Yahav L., Zion T., Meirowithz E., et al. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis 2013, 7:e522-e532. 10.1016/j.crohns.2013.03.009.
92. Pavlidis P., Forbes A., Bogdanos D.P. Anti-GP2 antibodies in inflammatory bowel disease patients with ileal pouch. J Crohns Colitis 2013, 7:e602-e603. 10.1016/j.crohns.2013.06.010.
93. Somma V., Ababneh H., Ababneh A., Gatti S., Romagnoli V., Bendia E., et al. The novel Crohn's disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract 2013, 2013:1-7. 10.1155/2013/683824.
94. Roggenbuck D., Reinhold D., Wex T., von Arnim U., Malfertheiner P., Sturm A., et al. Authors' response: antibodies to GP2, the major zymogen granule membrane glycoprotein, are specific for Crohn's disease and may reflect treatment response. Gut 2011, [gut.2010.237214]. 10.1136/gut.2010.237214.
95. Rieder F., Lopez R., Franke A., Wolf A., Schleder S., Dirmeier A., et al. Characterization of changes in serum anti-glycan antibodies in Crohn's Disease - a longitudinal analysis. PLoS One 2011, 6:e18172. 10.1371/journal.pone.0018172.
96. Joossens M., Van Steen K., Branche J., Sendid B., Rutgeerts P., Vasseur F., et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010, 16:58-67. 10.1002/ibd.20985.
97. Lakatos P.L., Altorjay I., Mándi Y., Lakatos L., Tumpek J., Kovacs A., et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?. Tissue Antigens 2008, 71:552-559. 10.1111/j.1399-0039.2008.01049.x.
98. Roggenbuck D., Humbel R.-L., Reinhold D., Bogdanos D.P., Conrad K., Laass M.W. Glycoprotein 2 antibodies in inflammatory bowel disease: no association with disease phenotype?. J Pediatr Gastroenterol Nutr 2013, 56:e5. 10.1097/MPG.0b013e318275fa77.
99. Lakatos P.L., Altorjay I., Szamosi T., Palatka K., Vitalis Z., Tumpek J., et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009, 15:365-374. 10.1002/ibd.20778.